HomeALKS • NASDAQ
Alkermes Plc
Follow
$32.65
0.37%
After Hours:(0.00%)0.00
$32.65
Closed: Apr 2, 6:21:29 PM GMT-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 429.99M | 13.91% |
Operating expense | 205.18M | -18.81% |
Net income | 146.50M | 29.90% |
Net profit margin | 34.07 | 14.02% |
Earnings per share | 1.05 | 377.27% |
EBITDA | 169.54M | 131.69% |
Effective tax rate | 14.22% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 751.67M | -2.82% |
Total assets | 2.06B | -3.78% |
Total liabilities | 590.59M | -36.74% |
Total equity | 1.46B | — |
Shares outstanding | 162.61M | — |
Price to book | 3.60 | — |
Return on assets | 19.32% | — |
Return on capital | 25.43% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 146.50M | 29.90% |
Cash from operations | 190.40M | 77.55% |
Cash from investing | -13.88M | 33.87% |
Cash from financing | -281.67M | -1.87% |
Net change in cash | -105.15M | 44.73% |
Free cash flow | 122.70M | 321.83% |
Previous close
$32.53
Day range
$32.05 - $32.81
Year range
$22.90 - $36.45
Market cap
5.31B USD
Avg Volume
1.63M
P/E ratio
14.84
Dividend yield
-
Primary exchange
NASDAQ
About
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
Founded
1987
Website
Employees
1,800
